Head‐to‐head comparison between plasma ptau‐217 and Flortaucipir‐PET in amyloid‐positive patients with cognitive impairment

Plasma measurements of phosphorylated tau (ptau) have emerged as promising biomarkers for Alzheimer’s disease (AD). Studies have shown strong associations between ptau and tau‐PET that are mainly driven by the difference between amyloid‐positive and amyloid‐negative patients. However, the relationship between ptau and tau‐PET is not well characterized within patients with AD. We conducted a head‐to‐head comparison between plasma ptau‐217 and tau‐PET in patients at the clinical stage of AD and assessed biomarker relationships with demographic and clinical variables.